​WeightWatchers Squeezes Higher After Unveiling New Low-Cost GLP-1 Treatment – Tyler Durden

WeightWatchers Squeezes Higher After Unveiling New Low-Cost GLP-1 Treatment Shares of heavily shorted WW International, also known as WeightWatchers, jumped as much as 27% on Tuesday morning after the weight-management company announced a new low-cost weight-loss drug offering, which is essentially a copycat of Novo Nordisk A/S’s Ozempic and Wegovy.  WW announced the addition of a new compounded semaglutide to its lineup to beat America’s obesity crisis sparked by the processed foods industrial complex. The new treatment starts at $129 per month, and each additional month will cost $189. This is significantly less than GLP-1 obesity treatments from big pharma, which cost north of $1,000 a…  — Continue at ZeroHedge News : Read More